AstraZeneca PLC released more key data from trials for the Covid-19 vaccine, stating that the shot was 76% effective in preventing Covid-19 with symptoms in a more complete analysis of the results of the study the company had previously provided. .
AstraZeneca said its latest data on vaccine efficacy was based on an analysis of 190 cases of symptomatic Covid-19 at trial, 49 more cases than the company had previously analyzed.
Despite the additional cases, the vaccine’s performance matched what AstraZeneca had first reported.
The London-based pharmacist had started firing earlier this week after providing preliminary trial data indicating his vaccine was 79% effective in 141 subjects.
An independent study oversight committee said the data was out of date, prompting the U.S. National Institute of Allergy and Infectious Diseases to issue an unusual statement that raised concerns from experts.